section 1 - World Intellectual Property Organization
section 1 - World Intellectual Property Organization
section 1 - World Intellectual Property Organization
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
37/2000<br />
13238 PCT Gazette - Section I - Gazette du PCT 14 Sep/sep 2000<br />
(54) N–PROTECTED SYNTHESIS ME-<br />
THOD FOR USE IN MAKING POR-<br />
PHYRINS<br />
SYNTHESE N–PROTEGEE CON-<br />
VENANT A LA PREPARATION DE<br />
PORPHYRINES<br />
(71) EMORY UNIVERSITY [US/US]; 2009<br />
Ridgewood Drive, Atlanta, GA 30322 (US).<br />
(72) NICKEL, Eric, G.; 8356–I Roswell Road,<br />
Atlanta, GA 30350 (US). LIEBESKIND,<br />
Lanny, S.; 2573 Kings Lake Court, Atlanta,<br />
GA 30345 (US).<br />
(74) JOHNSON, William, R. et al. / etc.;<br />
Needle & Rosenberg, P.C., 127 Peachtree<br />
Street, N.E., Suite 1200, Atlanta, GA 30303<br />
(US).<br />
(81) AU CA JP; EP (AT BE CH CY DE DK ES<br />
FI FR GB GR IE IT LU MC NL PT SE).<br />
(51) 7 C07D 207/38, 309/32, A61K 31/40,<br />
31/365, 31/38, 31/35, C07D 307/66,<br />
333/36, A61P 35/00<br />
(11) WO 00/53581 (13) A2<br />
(21) PCT/EP00/01721<br />
(22) 1 Mar/mar 2000 (01.03.2000)<br />
(25) en (26) en<br />
(30) MI99A000456 5 Mar/mar 1999<br />
(05.03.1999)<br />
(43) 14 Sep/sep 2000 (14.09.2000)<br />
(54) HETEROCYCLIC COMPOUNDS HA-<br />
VING ANTITUMOR ACTIVITY<br />
COMPOSES HETEROCYCLIQUES<br />
AYANT UNE ACTIVITE ANTITUMO-<br />
RALE<br />
(71) NOVUSPHARMA S.P.A. [IT/IT]; Piazza<br />
Durante, 11, I–20131 Milano (IT).<br />
(for all designated States except / pour tous<br />
les États désignés sauf US)<br />
(72, 75) MENTA, Ernesto [IT/IT]; (IT).<br />
CONTI, Marco [IT/IT]; (IT). PESCALLI,<br />
Nicoletta [IT/IT]; Via G.B. Stucchi, 110,<br />
I–20052 Monza (IT).<br />
(74) MINOJA, Fabrizio et al. / etc.; Bianchetti<br />
Bracco Minoja S.r.l., Via Rossini, 8, I–20122<br />
Milano (IT).<br />
(81) AE AL AM AT AU AZ BA BB BG BR BY<br />
CA CH CN CR CU CZ DE DK DM EE ES<br />
FI GB GD GE GH GM HR HU ID IL IN<br />
IS JP KE KG KP KR KZ LC LK LR LS LT<br />
LU LV MA MD MG MK MN MW MX NO<br />
NZ PL PT RO RU SD SE SG SI SK SL TJ<br />
TM TR TT TZ UA UG US UZ VN YU ZA<br />
ZW; AP (GH GM KE LS MW SD SL SZ<br />
TZ UG ZW); EA (AM AZ BY KG KZ MD<br />
RU TJ TM); EP (AT BE CH CY DE DK ES<br />
FI FR GB GR IE IT LU MC NL PT SE);<br />
OA (BF BJ CF CG CI CM GA GN GW ML<br />
MR NE SN TD TG).<br />
(51) 7 C07D 213/73, 417/06, 401/06, 413/06,<br />
233/88, A61K 31/44, 31/4439, 31/444,<br />
31/506, 31/501, 31/5355, 31/427, 31/4168,<br />
A91P 43/00, 25/28<br />
(11) WO 00/53582 (13) A1<br />
(21) PCT/JP00/01190<br />
IT<br />
(22) 1 Mar/mar 2000 (01.03.2000)<br />
(25) ja (26) ja<br />
(30) 11/57993 5 Mar/mar 1999<br />
(05.03.1999)<br />
(43) 14 Sep/sep 2000 (14.09.2000)<br />
(54) HETEROCYCLIC COMPOUNDS HA-<br />
VING EFFECT OF ACTIVATING<br />
NICOTINIC ACETYLCHOLINE<br />
RECEPTOR<br />
4 2<br />
COMPOSES HETEROCYCLIQUES<br />
POSSEDANT UN EFFET<br />
D’ACTIVATION DU RECEPTEUR<br />
4 2 DE L’ACETYLCHOLINE<br />
NICOTINIQUE<br />
(71) SUNTORY LIMITED [JP/JP]; 1–40, Dojimahama<br />
2–chome,<br />
Osaka 530–8203 (JP).<br />
Kita–ku, Osaka–shi,<br />
(for all designated States except / pour tous<br />
les États désignés sauf US)<br />
(72, 75) IMOTO, Masahiro [JP/JP];<br />
11–96–401, Ootani–cho, Nishinomiya–shi,<br />
Hyogo 662–0054 (JP). IWANAMI, Tatsuya<br />
[JP/JP]; 34–2–903, Yahata–cho 2–chome,<br />
Ashikaga–shi, Tochigi 326–0824 (JP). AKA-<br />
BANE, Minako [JP/JP]; 1–37–201, Sojiji<br />
1–chome, Ibaraki–shi, Osaka 567–0801<br />
(JP). TANI, Yoshihiro [JP/JP]; 9–38, Hoshimi–cho,<br />
(JP).<br />
Ibaraki–shi, Osaka 567–0843<br />
(74) KUSAMA, Osamu; Kusama Patent Office,<br />
7f Iwata Bldg., 5–12, Iidabashi 4–chome,<br />
Chiyoda–ku, Tokyo 102–0072 (JP).<br />
(81) AU CA CN JP KR US; EP (AT BE CH CY<br />
DE DK ES FI FR GB GR IE IT LU MC NL<br />
PT SE).<br />
(51) 7 C07D 237/22, C07K 5/06, C07D 257/04,<br />
405/12, 261/12, 213/81, 237/06, 207/26,<br />
213/82, 307/68, A61K 31/165, 31/42, 31/44<br />
(11) WO 00/53583<br />
(21) PCT/US00/06022<br />
(13) A1<br />
(22) 9 Mar/mar 2000 (09.03.2000)<br />
(25) en (26) en<br />
(30) 09/265,410 10 Mar/mar 1999<br />
(10.03.1999)<br />
US<br />
(43) 14 Sep/sep 2000 (14.09.2000)<br />
(54) INHIBITORS OF PROTEIN TYROSINE<br />
PHOSPHATASE<br />
INHIBITEURS DE LA TYROSINE<br />
PHOSPHATASE<br />
(71) PHARMACIA & UPJOHN AB [SE/SE];<br />
S–112 87 Stockholm (SE).<br />
(for all designated States except / pour tous<br />
les États désignés sauf US)<br />
(72, 75) LARSEN, Scott, D. [US/US]; 56 Naples<br />
Court, Kalamazoo, MI 49009 (US). MAY,<br />
Paul, D. [US/US]; 7890 North 32nd Street,<br />
Richland, MI 49083 (US). BLEASDALE,<br />
John, E. [GB/US]; 3230 Lites End Court,<br />
Portage, MI 49024 (US). LILJEBRIS,<br />
Charlotta [SE/SE]; S–741 92 Knivsta (SE).<br />
SCHOSTAREZ, Heinrich, Josef [US/US];<br />
3236 Lost Pine Way, Portage, MI 49024<br />
(US). BARF, Tjeerd [NL/SE]; S–753<br />
34 Uppsala (SE). NILSSON, Marianne<br />
[SE/SE]; S–762 94 Rimbo (SE).<br />
JP<br />
(74) MURPHY, Gerald, M.; Birch, Stewart,<br />
Kolasch & Birch, L.L.P., P.O. Box 747, Falls<br />
Church, VA 22040–0747 (US).<br />
(81) AE AL AM AT AU AZ BA BB BG BR BY<br />
CA CH CN CR CU CZ DE DK DM EE ES<br />
FI GB GD GE GH GM HR HU ID IL IN<br />
IS JP KE KG KP KR KZ LC LK LR LS LT<br />
LU LV MA MD MG MK MN MW MX NO<br />
NZ PL PT RO RU SD SE SG SI SK SL TJ<br />
TM TR TT TZ UA UG US UZ VN YU ZA<br />
ZW; AP (GH GM KE LS MW SD SL SZ<br />
TZ UG ZW); EA (AM AZ BY KG KZ MD<br />
RU TJ TM); EP (AT BE CH CY DE DK ES<br />
FI FR GB GR IE IT LU MC NL PT SE);<br />
OA (BF BJ CF CG CI CM GA GN GW ML<br />
MR NE SN TD TG).<br />
Published / Publiée :(c)<br />
(51) 7 C07D 239/96<br />
(11) WO 00/53584 (13) A1<br />
(21) PCT/JP00/01360<br />
(22) 6 Mar/mar 2000 (06.03.2000)<br />
(25) ja (26) ja<br />
(30) 11/61390 9 Mar/mar 1999 JP<br />
(09.03.1999)<br />
(43) 14 Sep/sep 2000 (14.09.2000)<br />
(54) PROCESS FOR PRODUCING QUINA-<br />
ZOLINE DERIVATIVE OR SALT THE-<br />
REOF<br />
PROCEDE DE PRODUCTION D’UN<br />
DERIVE QUINAZOLINE OU D’UN<br />
SEL DE CE DERIVE<br />
(71) FUJISAWA PHARMACEUTICAL CO.,<br />
LTD. [JP/JP]; 4–7, Doshomachi 3–chome,<br />
Chuo–ku, Osaka–shi, Osaka 541–8514 (JP).<br />
(for all designated States except / pour tous<br />
les États désignés sauf US)<br />
(72, 75) FUKAGAWA, Masayasu [JP/JP]; 48,<br />
Jinden, Kamiichimachi, Nakaniikawa–gun,<br />
Toyama 930–0365 (JP). IEDA, Shigeru<br />
[JP/JP]; 5–1–1, Mukogaoka, Sanda–shi,<br />
Hyogo 669–1544 (JP). TSUBOI, Hiroyuki<br />
[JP/JP]; 19–1, Ishizuminamimachi, Neyagawa–shi,<br />
Osaka 572–0024 (JP). GOTO,<br />
Shunsuke [JP/JP]; 5–5–35–701, Nankounaka,<br />
Suminoe–ku, Osaka–shi, Osaka<br />
559–0033 (JP). KAGARA, Kooji [JP/JP];<br />
17–12, Onoharanishi 3–chome, Mino–shi,<br />
Osaka 562–0032 (JP). UEMATSU, Ryoichi<br />
[JP/JP]; 2–62–107, Takamatsu–cho,<br />
Takarazuka–shi, Hyogo 665–0043 (JP).<br />
NISIWAKI, Masanori [JP/JP]; 38–17,<br />
Hashimotonishikarimata, Yawata–shi, Kyoto<br />
614–8334 (JP).<br />
(74) TABUSHI, Eiji; Fujisawa Pharmaceutical<br />
Co., Ltd.Osaka Factory, 1–6, Kashima<br />
2–chome, Yodogawa–ku, Osaka–shi, Osaka<br />
532–8514 (JP).<br />
(81) AE AL AM AT AU AZ BA BB BG BR BY<br />
CA CH CN CU CZ DE DK EE ES FI GB<br />
GD GE GH GM HR HU ID IL IN IS JP KE<br />
KG KR KZ LC LK LR LS LT LU LV MD<br />
MG MK MN MW MX NO NZ PL PT RO<br />
RU SD SE SG SI SK SL TJ TM TR TT UA<br />
UG US UZ VN YU ZA ZW; AP (GH GM<br />
KE LS MW SD SL SZ TZ UG ZW); EA<br />
(AM AZ BY KG KZ MD RU TJ TM); EP<br />
(ATBECHCYDEDKESFIFRGBGR<br />
IE IT LU MC NL PT SE); OA (BF BJ CF<br />
CG CI CM GA GN GW ML MR NE SN TD<br />
TG).